Home Tools
Log in
Cart

Oxaliplatin

Catalog No. T0164   CAS 61825-94-3
Synonyms: L-OHP

Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Oxaliplatin Chemical Structure
Oxaliplatin, CAS 61825-94-3
Pack Size Availability Price/USD Quantity
50 mg In stock $ 50.00
100 mg In stock $ 68.00
200 mg In stock $ 117.00
500 mg In stock $ 139.00
Bulk Inquiry
Get quote
Select Batch  
Purity: 99.93%
Purity: 99.63%
Purity: 98.47%
Purity: 98%
Purity: 97%
Contact us for more batch information
Biological Description
Chemical Properties
Storage & Solubility Information
Description Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.
In vitro METHODS: Human colon cancer cells HT29, SW620, WiDr and LS174T were treated with Oxaliplatin (0.001 ng/ml-100 µg/mL) for 24 h, and cytotoxicity was detected using MTT method.
RESULTS: Oxaliplatin was cytotoxic to HT29, SW620, WiDr and LS174T cells, with IC50s of 0.33, 1.13, 0.13 and 0.19 μg/mL, respectively.[1]
METHODS: Human colon cancer cells HCT116 WT and CHK2 KO were treated with Oxaliplatin (40 µM) for 24-96 h. Apoptosis was detected by Flow Cytometry.
RESULTS: Oxaliplatin treatment for 24-96 h increased apoptosis levels in WT and CHK2-KO cell lines. From 24-72 h, the apoptosis level of WT cells was consistently twofold lower than that of CHK2 KO cells. However, treatment for 96 h resulted in the same level of apoptosis in WT and CHK2-KO cells (85%). [2]
METHODS: Human oral squamous cell carcinoma cells CAL27 and SCC25 were treated with Oxaliplatin (31.25-125 μM) and Oxaliplatin (25-100 μM) for 12-36 h. Cell migration was detected using the Wound-healing method.
RESULTS: Oxaliplatin inhibited the migration of CAL27 and SCC25 cells in a dose-dependent manner. [3]
In vivo METHODS: To detect anti-tumor activity in vivo, Oxaliplatin (5 mg/kg) and piperlongumine (2.5 mg/kg) were administered intraperitoneally once a day for twenty-four days to BALB/c nu/nu mice bearing human colorectal carcinoma tumor HCT-116.
RESULTS: The combination of Oxaliplatin and piperlongumine significantly inhibited tumor growth, and piperlongumine sensitized tumors to Oxaliplatin through ROS-mediated apoptosis in vivo. [4]
METHODS: To model platinum-induced painful peripheral neuropathy, Oxaliplatin (3 mg/kg/day) was injected intraperitoneally into C57BL6J mice for five days with five days of rest for two cycles.
RESULTS: Mice in the Oxaliplatin-treated group exhibited significant mechanical anomalous pain. the Oxaliplatin group exhibited significant cold nociceptive hypersensitivity in the hindfoot. [5]
Kinase Assay Binding experiments of electrophysiology: CHO cells expressing the subunit of the voltage-dependent L-type Ca2+ channel are cultrured in medium without serum in the presence of different concentrations of Nisoldipine. Then Ca2+ channel current elicited from a holding potential of -100 mV or -50 mV is recorded at room temperature with the whole-cell configuration of the patch-clamp method using the List EPC-7 patch-clamp amplifer and pClamp software. The concentration of competitor inhibiting 50% of the specific binding represents IC50.
Cell Research The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control(Only for Reference)
Synonyms L-OHP
Molecular Weight 397.29
Formula C8H14N2O4Pt
CAS No. 61825-94-3

Storage

keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

Ethanol: < 1 mg/mL (insoluble)

DMSO: 50 mg/mL (125.85 mM), DMSO can inactivate Oxaliplatin's activity

H2O: 3 mg/mL (7.55 mM), ultrasonic and warming and heat to 60°C

DMF: 1.67 mg/mL (4.20 mM), sonification is recommended.

TargetMolReferences and Literature

1. Nannizzi S, et al. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemother Pharmacol. 2010 Aug;66(3):547-58. 2. Pires IM, et al. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br J Pharmacol. 2010 Mar;159(6):1326-38. 3. Li D, et al. Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS. Aging (Albany NY). 2021 Jan 20;13(3):4242-4257. 4. Chen W, et al. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis. 2019 Aug 8;10(8):600. 5. Ta LE, et al. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain. 2009 Feb 26;5:9. 6. Zhou Y, Yang L, Xiong L, et al. KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3β signaling[J]. Journal of Cancer. 2021, 12(12): 3741. 7. Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382. 8. Yang P, Liu W, Fu R, et al. Cucurbitacin E Chemosensitizes Colorectal Cancer Cells via Mitigating TFAP4/Wnt/β-Catenin Signaling[J]. Journal of Agricultural and Food Chemistry. 2020 9. Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation[J]. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-15. 10. Huang Y, Wang H, Hao Y, et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity[J]. Nature Cell Biology. 2020: 1-12.(22-6 , 716–727)

TargetMolCitations

1. Chao S, Zhang F, Yan H, et al.Targeting intratumor heterogeneity suppresses colorectal cancer chemoresistance and metastasis.EMBO reports.2023: e56416. 2. Jiang Y, Feng Y, Huang J, et al.LAD1 promotes malignant progression by diminishing ubiquitin-dependent degradation of vimentin in gastric cancer.Journal of Translational Medicine.2023, 21(1): 1-15. 3. Feng Y, Cao Z, Xu A, et al.Evaluation of toxicity and mutagenicity of oxaliplatin on germ cells in an alternative in vivo model Caenorhabditis elegans.Food and Chemical Toxicology.2023: 113902. 4. Yu Y, Wu T, Zhang X, et al.Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells.European Journal of Pharmacology.2023: 175986. 5. Zhang Z, Ye J, Liu X, et al.Huangqi Guizhi Wuwu decoction alleviates oxaliplatin-induced peripheral neuropathy via the gut-peripheral nerve axis.Chinese Medicine.2023, 18(1): 1-15. 6. Feng W Q, Zhang Y C, Gao H, et al.FOXD1 promotes chemotherapy resistance by enhancing cell stemness in colorectal cancer through β‑catenin nuclear localization.Oncology Reports.2023, 50(1): 1-14. 7. Li J, Lv J, Chen Y, et al.Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance.Gene.2023: 147323. 8. Zhao L, Liu S, Zhang X, et al.Satellite glial cell-secreted exosomes after in-vitro oxaliplatin treatment presents a pro-nociceptive effect for dorsal root ganglion neurons and induce mechanical hypersensitivity in naïve mice.Molecular and Cellular Neuroscience.2023: 103881. 9. Liu M, Mai J W, Luo D X, et al.NFATc2-dependent Epigenetic Downregulation of the TSC2/Beclin-1 Pathway is Involved in Neuropathic Pain Induced by Oxaliplatin.Molecular Pain.2023: 17448069231158289. 10. Glorieux C, Xia X, You X, et al. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Journal of Advanced Research. 2021
11. Huang Y, Wang H, Hao Y, et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. Nature Cell Biology. 2020: 1-12.(22-6 , 716–727) 12. Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-15 13. Zhou Y, Yang L, Xiong L, et al. KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3β signaling. Journal of Cancer. 2021, 12(12): 3741. 14. Lee E J, Yang J H, Choi J G, et al. Augmented Antitumor Effect of Unripe Rubus coreanus Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model. Cells. 2022, 11(18): 2876. 15. Lin W, Zou H, Mo J, et al. Micro1278 Leads to Tumor Growth Arrest, Enhanced Sensitivity to Oxaliplatin and Vitamin D and Inhibits Metastasis via KIF5B, CYP24A1, and BTG2, Respectively. Frontiers in Oncology. 2021 Mar 11;11:637878. doi: 10.3389/fonc.2021.637878. eCollection 2021. 16. Shen X, Zhang Y, Xu Z, et al. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response. Cell Death & Disease. 2022, 13(4): 1-13 17. Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation. Journal of chemical information and modeling. 2019, 59(10): 4374-4382. 18. Yang P, Liu W, Fu R, et al. Cucurbitacin E Chemosensitizes Colorectal Cancer Cells via Mitigating TFAP4/Wnt/β-Catenin Signaling. Journal of Agricultural and Food Chemistry. 2020 Nov 18. doi: 10.1021 19. Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma by targeting CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Molecular Therapy-Nucleic Acids. 2022 20. Qiao S, Lu W, Glorieux C, et al. Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. Oncogene. 2021: 1-13. 21. Su C, Cheng C, Rong Z, et al.Repurposing fluphenazine as an autophagy modulator for treating liver cancer.Heliyon.2023 22. Lee E J, Kim Y S, Kim J H, et al.Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.Phytomedicine.2024: 155370.
Hide

Related compound libraries

This product is contained In the following compound libraries:
Anti-Cancer Approved Drug Library Anti-Cancer Active Compound Library Tyrosine Kinase Inhibitor Library Anti-Cancer Clinical Compound Library Anti-Cancer Drug Library Orally Active Compound Library Inhibitor Library Human Metabolite Library Drug-induced Liver Injury (DILI) Compound Library Clinical Compound Library

Related Products

Related compounds with same targets
N-Nitroso-N-methylurea Procarbazine hydrochloride Bendamustine hydrochloride Cyclophosphamide hydrate KCC-07 Illudin M Semustine Busulfan

TargetMolDose Conversion

You can also refer to dose conversion for different animals. More

TargetMol In vivo Formulation Calculator (Clear solution)

Step One: Enter information below
Dosage
mg/kg
Average weight of animals
g
Dosing volume per animal
ul
Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
Calculate Reset

TargetMolCalculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
=
X
X

Molarity Calculator allows you to calculate the

  • Mass of a compound required to prepare a solution of known volume and concentration
  • Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Concentration of a solution resulting from a known mass of compound in a specific volume
See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box

X
=
X

Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box

=
/

Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

g/mol

Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

bottom

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords

Oxaliplatin 61825-94-3 Autophagy Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA Alkylator/Crosslinker DNA/RNA Synthesis L-OHP DNA cross-links anticancer Inhibitor apoptosis inhibit inhibitor

 

TargetMol